Abbott Laboratories (ABT) — ESG & Values Scores

Environment story

Abbott's 10-K disclosures contain no quantified Scope 1, 2, or 3 greenhouse-gas emissions data, no stated net-zero target year, and no disclosed renewable-electricity percentage. The filing references an accrued legal/environmental exposure reserve without specifying the underlying issue. This research finding is descriptive and does not constitute investment advice.

Criticisms on file

10-K MD&A discloses an aggregate accrued liability of approximately $175 million (range $170M-$180M) covering 'legal proceedings and environmental exposures,' without itemized disclosure of the environmental component.
Source: ABT_10k.txt - MD&A, Critical Accounting Policies, Litigation section

Disclosed initiatives

Capital expenditure on manufacturing/R&D facilities

Abbott reported $2.2 billion in capital expenditures in 2025, principally for upgrading and expanding manufacturing and R&D facilities and equipment; the filing does not specify any decarbonization-specific allocation.

Unquantified

Social story

Available filings do not disclose a CEO-to-median-worker pay ratio figure, workforce turnover rate, or supply-chain human-rights audit results, though the proxy references a 'CEO pay ratio' section not included in the provided excerpt. No documented union-suppression activity or strikes within the last 24 months were identified in the risk factors, which only mention labor disputes as a generic forward-looking risk category. Board gender representation appears at approximately 50%. This is a factual research summary, not a recommendation.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Board diversity refreshment

Abbott added five new independent directors in the last five years, including candidates with varied professional backgrounds.

Board composition

Governance story

Abbott maintains a single-class share structure and board independence of approximately 92% (11 of 12 nominees), both favorable governance markers. However, the company faces multiple active regulatory and legal proceedings, including a 2022 FDA consent decree tied to an infant formula recall, an ongoing related derivative shareholder action, and multiple contested IRS Statutory Notices of Deficiency (2017-2020 tax years) plus a Malaysian tax assessment under appeal. This is descriptive research output only and not investment advice.

Criticisms on file

FDA consent decree (May 2022) following voluntary recall of powder infant formula manufactured at Sturgis, Michigan facility; related shareholder derivative action ongoing as of the 2026 proxy filing, with Abbott advancing defense costs for directors/officers.
Source: ABT_10k.txt - Risk Factors; ABT_proxy.txt - Other Matters section
Multiple IRS Statutory Notices of Deficiency for 2017-2020 tax years totaling over $1 billion in proposed adjustments, contested by Abbott in U.S. Tax Court.
Source: ABT_10k.txt - MD&A, Taxes on Earnings section
Malaysian tax authority assessment of $413 million (2023 tax year) upheld by Penang High Court in October 2025; Abbott has appealed to the Malaysian Court of Appeals.
Source: ABT_10k.txt - MD&A, Taxes on Earnings section

Disclosed initiatives

Fully independent board committees

Audit, Compensation, Nominations and Governance, and Public Policy Committees are composed entirely of independent directors.

Governance oversight structure
Public Policy Committee oversight

Committee has explicit oversight of political contributions, lobbying activities, trade association memberships, and sustainability/social responsibility policies.

Governance process

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Abbott Laboratories. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Abbott Laboratories in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)